S. Strickland, D. Andorsky, T. Brümmendorf, Susanne Saußele, F. Mahon, V. Pilipovic, Yifan Zhang, P. Schuld, A. Hochhaus
{"title":"CML-590 ASC4START:阿西米尼与尼洛替尼在新诊断的Ph+慢性粒细胞白血病慢慢性期(CML-CP)患者中的3b期、开放标签、随机研究","authors":"S. Strickland, D. Andorsky, T. Brümmendorf, Susanne Saußele, F. Mahon, V. Pilipovic, Yifan Zhang, P. Schuld, A. Hochhaus","doi":"10.1016/s2152-2650(23)00566-9","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":10370,"journal":{"name":"Clinical Lymphoma Myeloma and Leukemia","volume":"2013 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"POSTER: CML-590 ASC4START: A Phase 3b, Open-Label, Randomized Study of Asciminib vs Nilotinib in Patients With Newly Diagnosed Ph+ Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)\",\"authors\":\"S. Strickland, D. Andorsky, T. Brümmendorf, Susanne Saußele, F. Mahon, V. Pilipovic, Yifan Zhang, P. Schuld, A. Hochhaus\",\"doi\":\"10.1016/s2152-2650(23)00566-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":10370,\"journal\":{\"name\":\"Clinical Lymphoma Myeloma and Leukemia\",\"volume\":\"2013 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lymphoma Myeloma and Leukemia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/s2152-2650(23)00566-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma Myeloma and Leukemia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s2152-2650(23)00566-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
POSTER: CML-590 ASC4START: A Phase 3b, Open-Label, Randomized Study of Asciminib vs Nilotinib in Patients With Newly Diagnosed Ph+ Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)